Medidata and Syapse are partnering up to help trial sponsors accelerate clinical research into precision medicine for use in oncology. The two companies have teamed up with the National Cancer Institute (NCI) on a new program that will allow cancer patients to receive personalized treatment plans tailored specifically to their unique genetic profile. The pair hope to build a range of solutions that optimise trial eligibility criteria and make it easier for specialists to identify and enrol patients, said Glen de Vries, president of Medidata.
Medidata and Syapse are partnering up to help trial sponsors accelerate clinical research into precision medicine for use in oncology. Syapse software powers precision medicine for nearly 300 US hospitals, while Medidata's cloud-based technology and data analytics systems are used by 18 of the top 25 pharmaceutical firms. The pair hope to build a range of solutions that optimise trial eligibility criteria and make it easier for specialists to identify and enrol patients, said Glen de Vries, president of Medidata.